Eurofins Expands Its Leadership in Biopharmaceutical Services with the Acquisition of Alphora Research, Inc.
June 13 2017 - 1:30AM
Business Wire
Regulatory News:
Eurofins Scientific (Paris:ERF) (EUFI.PA), a world leader in
biopharmaceutical testing, announces the acquisition of Alphora
Research Inc. (“Alphora”), a full service contract research,
development and manufacturing organization (CRDMO) for complex and
niche small molecule active pharmaceutical ingredients (APIs),
based in Mississauga, Ontario, Canada.
Alphora has extensive capabilities in multi-step syntheses, as
well as the development of cytotoxic and highly potent APIs. It
operates two fully integrated facilities to address a wide array of
API challenges, providing a full spectrum of complex API
development, testing and manufacturing services. As such the
company supports biopharmaceutical companies from the preclinical
phase through to commercialization of niche products, and is an
ideal complement to Eurofins’ discovery and other biopharmaceutical
testing activities. Alphora has grown rapidly since it was founded
in 2003, and expects to generate revenues in excess of CAD 30m in
2017, with organic growth and EBITDA margin well above Eurofins’
objectives.
Alphora’s expertise in API development, testing and
manufacturing provides Eurofins entry into the dynamic and growing
CRDMO market. It is uniquely positioned to capitalize on the strong
growth and positive trends in the API industry, which are driven by
the increasing importance of outsourcing in biopharmaceutical
R&D, limited API manufacturing capacity in North America, and
increased funding for early stage discovery and development.
Furthermore, Alphora is ideally positioned to support the
development of discovery candidates that emerge from Eurofins’
extensive drug discovery platform. In addition to Eurofins’
existing capabilities in preclinical, clinical, and GMP product
testing, this acquisition of Alphora further strengthens the
Group’s highly compelling and integrated offering to enable clients
to progress through the entire drug development process.
Comment from Dr. Gilles Martin, Eurofins CEO: “We are pleased to
welcome Alphora to the Eurofins Group. Alphora’s competencies and
footprint further strengthen Eurofins’ global leadership in the
rapidly-growing biopharmaceutical testing market. We look forward
to strengthening their portfolio and operating footprint by
providing access to the full range of services and capabilities of
the Group.”
For more information, please visit
www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter
sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and
that it is also one of the global independent market leaders in
certain testing and laboratory services for agroscience, genomics,
discovery pharmacology and for supporting clinical studies. In
addition, Eurofins is one of the key emerging players in specialty
clinical diagnostic testing in Europe and the USA. With over 28,000
staff in 310 laboratories across 39 countries, Eurofins offers a
portfolio of over 130,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170612005978/en/
Eurofins ScientificInvestor RelationsPhone: +32 2 766
1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Sep 2023 to Sep 2024